Tuesday, November 6, 2007

Emerging drugs for the treatment of glioblastoma

Bevacizumab (Avastin) is an angiogenesis inhibitor that is being used in the treatment of glioblastoma multiforme (GBM). AQ4N (Banoxantrone) is a prodrug that becomes active in hypoxic regions (i.e., tumor) that is also being examined as a useful chemotherapeutic agent for GBM.

No comments: